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plus 60Gy with 3DCRT). In 2012, a new relapse was operated on subtotal surgery to avoid sensitive aphasia (as seen on post-
surgery MRI) We compared a total dose treatment of 36Gy, delivered in 20 sessions of 1.8Gy per fraction with 3DCRT, IMRT and
RapidArc®.
Results. 3DCRT: V95: 91%/V100:61% D95: 33.6Gy/D100: 28.8Gy/Brainstem: Dmaximum: 35Gy, Dmedian: 18Gy Visual pathways:
Dmaximum: 28.2Gy, Dmedian: 19Gy IMRT: V95: 99.97%/V100: 91.05% D95: 35.65%/D100: 33.67%/Brainstem: Dmaximum: 35.07%,
Dmedia: 19.91GyVisual pathway:Dmaximum: 13.72Gy/Dmedian: 11.3GyRAPIDARC:V95: 99.98%/V100: 91.8%D95: 35.42Gy/D100:
33.16Gy/Brainstem: Dmaximum: 36.13Gy, Dmedian: 17.4Gy Visual pathway: Dmaximum: 12.7Gy/Dmedian: 10.13Gy.
Conclusions. We conclude that the three techniques analysed can achieve good cobertures of PTV, sparing the different OARs and
eloquent areas.
http://dx.doi.org/10.1016/j.rpor.2013.03.133
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Introduction. The high degree glial tumors account for 2% of neoplasms in accident. They are aggressive tumors that require
multidisciplinary approach with surgery, radiotherapy and chemotherapy.
Objective. Analyzed, in a retrospective series of malignant glial tumors, treatments performed, results and acute and chronic
morbidity resulting therefrom.
Material and methods. Between February 2008 and February 2012 we evaluated 109 patients with primary CNS malignancies (54%
male and 46% female) with a median age of 61 years. Glioblastoma Multiforme were 82%, 11% Anaplastic Astrocytoma, 3%
Anaplastic Oligoastrocytoma, 4% Anaplastic oligodendroglioma and 6% histological conﬁrmation could not be obtained so it was
based on imaging test. 94% of patients were operated: 28% by total resection, 47% by partial resection and 19% exclusive biopsy.
97% of patients received adjuvant treatment: 84% RT+QT (Stupp scheme), 8% exclusive RT, 6% RT+QT in clinical trial and 3%
none. In 97% of patients we planned 3D CRT and in 3% Fractionated Stereotactic Radiotherapy. Median radical treatment dose
was 60Gy and 35Gy in palliative treatments.
Results. Median follow-up was 252 days. Toxicity assessed by CTCAE v4.0: of the 97 patients who received adjuvant treatment
with QT, 19% had thrombocytopenia≥grade II and 24%≥grade II leukopenia. 97% of them showed no memory impairment and
94% had no cognitive impairment. The surgical site failure occurred in 88% of patients, the remote failure occurred in 9% of
patients and 3% in both.
Conclusions. The high-grade glial tumors are tumors of poor prognosis with short survival being achieved discreetly extend thanks
to the combination of treatments.
http://dx.doi.org/10.1016/j.rpor.2013.03.134
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Purpose. To evaluate the survival of patients with newly diagnosed Glioblastoma Multiforme depending on the surgery performed.
Materials and methods. From April 2002 till January 2012, 82 patients (43 male and 39 female) mean age 63.3 (range from 29
to 82) with newly diagnosed Glioblastoma Multiforme was treated in our hospital. The treatment protocol consisted of total
surgery, partial surgery or biopsy only followed by external radiation therapy (6000 cGy in 30 fractions with conformal radio-
therapy technique) and concurrent chemotherapy with Temozolomide (75mg/m2/day) and adjuvant Temozolomide (TMZ)
monotherapy for 6 cycles (150–200mg/m2/5days). The median survival was evaluated depending on the type of surgery per-
formed. Total surgery was realized in twenty-nine patients (35.4%), ten patients (12.2%) were treated by partial surgery and
biopsy only was made in forty-three patients (52.2%). Survival was calculated using Kaplan–Meier and Long Rank (Mantel Cox)
methods.
Results. Overall survival for our patients was 14.5 months. Two patients who were diagnosed on April 2006 and December 2010
having undergone biopsy and total surgery respectively are still alive. Twenty-eight patientswere treated by total surgery followed
by concurrent chemotherapy–radiotherapy (QTRT) with TMZ and adjuvant TMZ with a median survival of 18 months. Partial
surgery followed by concurrent QTRT and adjuvant TMZ was realized in 10 patients with a median survival of 19.9 months.
Forty-two patients were not treated by surgery and received treatment which consisted of concurrent QTRT and adjuvant TMZ
with a median survival of 10.8 months. The longer survival was 68 months in a patient who was treated by total surgery followed
by concurrent QTRT and adjuvant TMZ. According to the Long Rank method a signiﬁcant median survival difference is observed
between biopsy and partial surgery with a p=0.016 and Biopsy and total surgery also, with a p=0.004. There is no difference
between total and partial surgery with a p=0.861.
